Wednesday’s Highlights at Noon: Goodrich Petroleum (GDP), SunPower (SPWR), Chesapeake Energy (CHK), Karyopharm Therapeutics (KPTI), McKesson (MCK)

By Carrie Williams

So far Wednesday, May 20, NASDAQ is up 2.49% and the S&P is up 1%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Goodrich Petroleum (GDPResearch Report), SunPower (SPWRResearch Report), Chesapeake Energy (CHKResearch Report), Karyopharm Therapeutics (KPTIResearch Report) and McKesson (MCKResearch Report).

Goodrich Petroleum is up 8.31% in midday trading to $7.30. Shares opened today at $6.74. The company has a 52-week low of $2.40 and a 52-week high of $13.34. On the Street’s front, the average 12-month analyst price target for the stock is $9.50, marking a 40.95% potential upside from current levels. In a report issued on May 8, Northland Securities analyst Jeff Grampp assigned a Buy rating on GDP, with a price target of $10.00, which implies an upside of 48% from current levels. Separately, on April 21, Roth Capital’s John M. White downgraded the stock to Hold and has a price target of $6.50. Over the last 3 months, the insider sentiment on Goodrich Petroleum has been positive based on 29 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

SunPower is down -7.8% in midday trading to $7.09. Shares opened today at $7.69. The company has a 52-week low of $4.03 and a 52-week high of $16.04. On the Street’s front, the average 12-month analyst price target for the stock is $7.38, marking a -4.03% potential downside from current levels. In a report issued on May 10, Credit Suisse analyst Michael Weinstein W. assigned a Buy rating on SPWR, with a price target of $10.00, which implies an upside of 30% from current levels. Separately, on May 8, Oppenheimer’s Colin Rusch maintained a Hold rating on the stock . In the last 30 days, insiders purchased $62.24K worth of SPWR shares.

Chesapeake Energy is up 7.79% in midday trading to $13.15. Shares opened today at $12.20. The company has a 52-week low of $7.77 and a 52-week high of $480.00. On the Street’s front, the average 12-month analyst price target for the stock is $16.50, marking a 35.25% potential upside from current levels. In a report issued on May 13, UBS analyst Lloyd Byrne reiterated a Sell rating on CHK, with a price target of $5.00, which reflects a potential downside of -59% from last closing price. Separately, on March 16, Morgan Stanley’s Devin McDermott maintained a Hold rating on the stock and has a price target of $50.00.

See today’s analyst top recommended stocks >>

Karyopharm Therapeutics is up 6.28% in midday trading to $19.12. Shares opened today at $17.99. The company has a 52-week low of $5.02 and a 52-week high of $29.61. On the Street’s front, the average 12-month analyst price target for the stock is $31.38, marking a 74.43% potential upside from current levels. In a report issued on May 14, H.C. Wainwright analyst Edward White reiterated a Buy rating on KPTI, with a price target of $40.00, which represents a potential upside of 122% from where the stock is currently trading. Separately, on April 7, Wedbush’s David Nierengarten reiterated a Hold rating on the stock and has a price target of $25.00. Over the last 3 months, the insider sentiment on Karyopharm Therapeutics has been negative based on 43 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

McKesson is up 6.17% in midday trading to $148.74. Shares opened today at $140.10. The company has a 52-week low of $112.60 and a 52-week high of $172.18. On the Street’s front, the average 12-month analyst price target for the stock is $167.57, marking a 19.61% potential upside from current levels. In a report released yesterday, J.P. Morgan analyst Lisa Gill maintained a Buy rating on MCK, with a price target of $187.00, which represents a potential upside of 33% from where the stock is currently trading. Separately, on April 22, Credit Suisse’s Jailendra Singh initiated coverage with a Hold rating on the stock and has a price target of $146.00. In the last 30 days, insiders purchased $14.55K worth of MCK shares.

Trending Stocks Based on Insider Activity >>